The Ataxia Charlevoix-Saguenay Foundation has received several innovative research proposals again this year. The Foundation would like to thank the applicants for their interest in the Ataxia Charlevoix-Saguenay and for the high quality of their submissions.
8 major projects will be funded for 2019-2020 with the goal of developing a treatment for the Ataxia Charlevoix-Saguenay.
Note to researchers and pharmaceutical companies – Both models of ARSACS transgenic mice now available at the Jackson Laboratory.
Both ARSACS transgenic mouse models, the Sacs Knock Out mouse (# 033221) and the Sacs Knock In R272C mouse (# 033385), are now available for sell on the Jackson Laboratory website www.jax.org.
Thanks to the financial support of the Ataxia Charlevoix-Saguenay Foundation, the mice generated and characterized by the ARSACS researcher team demonstrate similarities to the disease found in humans (Larivière et al., 2015 and Larivière et al., 2019).
For any questions, please contact the Ataxia Charlevoix-Saguenay Foundation at the following email address: firstname.lastname@example.org
Over the years, a greater collaboration has developed among ARSACS researchers. See a representation of the network of collaboration produced by Mathieu Blais.
The Ataxia Charlevoix-Saguenay Foundation cordially invites you to its annual fundraising Le Diner des Producteurs (13th edition)
under the honorary presidency of Mr. Jacques Foisy, Chairman of the Board and Managing Partner, Novacap. Invitation.
On June 11th, thanks to Manon Valiquette, Sonia Gobeil representing the Foundation had the pleasure of visiting the Institute for Research in Immunology and Cancer (IRCI) in Montreal and discovering extraordinary people who are very passionate about their work. Their ARSACS project consists in optimizing active molecules aimed at producing a reversal of the ARSACS phenotype in an In Vivo model. Thank you very much for your time. For more information.
The acronym “ARSACS” enters the life of Susanna de Luca and Paolo Arrigoni when their young child was diagnosed with ARSACS. Paolo joined the Board of Directors of the Ataxia Charlevoix-Saguenay Foundation in 2018 and, after having participated in the international symposium on ARSACS in Montreal, concluded that a point of reference and support was necessary in Europe, especially since several cases have been identified.
In December 2018, these parents created the ARSACS Organizzazione Di Volontariato (ARSACS ODV) based in Milan, Italy. Like the Ataxia Charlevoix-Saguenay Foundation, it is an organisation of volunteers, with a legal status, working in close collaboration with the Foundation. ARSACS ODV wishes to increase the awareness of ARSACS in Europe, to be a point of reference and support and to help finance the research projects via the Foundation.
Dr. Brais will be presenting “New insights on ARSACS lead to a search for candidate compounds“ at the 6th International Meeting on Spastic Paraparesis and Ataxia on September 20-21 2019 in Nice, France. The program includes plenary talks from leaders in the field of spinocerebellar diseases (dominant and recessive forms of cerebellar ataxias and spastic paraplegias)
On April 25th in Quebec City, Sonia Gobeil had the pleasure of meeting Dr. Esther Becker (Oxford University) and attending her conference on the cerebellum entitled “New Insights into Cerebellar Disorders”. Summary.
Dr. Cynthia Gagnon, member of the ARSACS research team, at the International Ataxia Research Conference
Dr. Cynthia Gagnon will be presenting on the Natural History, Biomarkers and Endpoints for ARSACS at the November 2019 International Ataxia Research Conference in Washington, DC
If you or a family member has received an ARSACS diagnostic, you are invited to register. It is easy and simple.
The registry is available in 4 languages English, French Spanish and in Italian. This is a way for you to support the cause.